维布妥昔单抗及靶向CD30的嵌合抗原受体T细胞在淋巴瘤治疗中的研究进展

CD30是一种细胞表面抗原，在正常活化的淋巴细胞上低表达，但是在多种淋巴瘤细胞上高表达，因此成为淋巴瘤治疗的靶抗原之一。抗体结合药物维布妥昔单抗（brentuximab vedotin, BV）与CD30结合后能快速内化进入肿瘤细胞内部诱导凋亡，在临床应用中疗效显著。此外，靶向CD30 嵌合抗原受体T细胞治疗(chimeric antigen receptor-modified T cell, CAR-T)在临床研究中安全、有效、耐受性好，为复发/难治淋巴瘤患者带来希望。本文就维布妥昔单抗及靶向CD30 CAR-T细胞在淋巴瘤治疗中的研究进展进行综述。

Brentuximab vedotin and anti-CD30 chimeric antigen receptor-modified T cells in treatment of lymphoma: research progress

CD30 is a cell surface antigen with low expression on normal activated lymphocytes, but high expression on the surface of various lymphoma cells, so it has become one of the target antigens for lymphoma therapy. The antibody-binding drug brentuximab vedotin (BV) can be rapidly internalized into tumor cells to induce apoptosis after binding to CD30, and it has a significant curative effect in clinical application. In addition, anti-CD30 chimeric antigen receptor-modified T cell(CAR-T) therapy is safe, effective and well tolerated in clinical studies, bringing hope to patients with relapsed/refractory lymphoma . This article reviews the research progress of brentuximab and anti-CD30 CAR-T cell in the treatment of lymphoma.